Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGENASDAQ:GLPGNASDAQ:INDVNASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$41.96+1.9%$38.38$26.20▼$63.50$1.90B1.38555,081 shs637,466 shsGLPGGalapagos$27.42-2.8%$27.23$22.36▼$31.23N/A0.07249,328 shs322,509 shsINDVIndivior$14.01+0.8%$11.67$7.33▼$16.98$1.92B0.661.11 million shs878,830 shsRAPPRapport Therapeutics$10.92-1.0%$10.77$6.43▼$29.74$402.57MN/A166,741 shs104,160 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+1.89%-5.67%+4.43%+5.32%+15.37%GLPGGalapagos-2.83%-4.66%-5.42%+6.20%+6.11%INDVIndivior+0.79%+0.86%+24.09%+42.67%-11.66%RAPPRapport Therapeutics-1.00%-2.41%+8.76%+12.35%+1,091,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.3888 of 5 stars3.51.00.00.02.14.20.0GLPGGalapagos0.1952 of 5 stars0.82.00.00.01.30.00.6INDVIndivior2.3518 of 5 stars1.65.00.00.02.41.71.9RAPPRapport Therapeutics1.2634 of 5 stars3.50.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$94.60125.45% UpsideGLPGGalapagos 1.50Reduce$25.33-7.61% DownsideINDVIndivior 3.25Buy$15.007.07% UpsideRAPPRapport Therapeutics 3.00Buy$32.67199.15% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, INDV, GLPG, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$28.004/8/2025RAPPRapport TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/AGLPGGalapagos$298.31MN/A$0.71 per share38.87$47.57 per shareN/AINDVIndivior$1.19BN/A$1.83 per share7.64($2.52) per shareN/ARAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)INDVIndivior$2M-$0.31N/A8.19N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)Latest RAPP, INDV, GLPG, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A15.8215.82GLPGGalapagosN/A7.957.86INDVIndiviorN/A0.880.72RAPPRapport TherapeuticsN/A31.0131.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%GLPGGalapagos32.46%INDVIndivior60.33%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%GLPGGalapagos2.91%INDVIndiviorN/ARAPPRapport TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableGLPGGalapagos1,310N/AN/AOptionableINDVIndivior1,051N/AN/ANot OptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ARAPP, INDV, GLPG, and APGE HeadlinesRecent News About These CompaniesAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)June 12, 2025 | marketbeat.comStifel reiterates buy rating for Rapport Therapeutics stockJune 5, 2025 | uk.investing.comRapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical PipelineJune 4, 2025 | nasdaq.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 16% - Still a Buy?June 4, 2025 | marketbeat.comRapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate UpdatesJune 2, 2025 | globenewswire.comRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare ConferenceMay 27, 2025 | globenewswire.comRapport Therapeutics (RAPP) to Release Quarterly Earnings on MondayMay 27, 2025 | marketbeat.comRapport Therapeutics to Host 2025 Investor and Analyst DayMay 21, 2025 | globenewswire.comCompanies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In GrowthMay 17, 2025 | finance.yahoo.comRapport Therapeutics Reports Q1 2025 Financial ResultsMay 10, 2025 | tipranks.comOptimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 DevelopmentsMay 8, 2025 | tipranks.comPromising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.May 8, 2025 | tipranks.comRapport Therapeutics Reports First Quarter 2025 Financials and Provides Business UpdateMay 8, 2025 | globenewswire.comInductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI PlatformMay 7, 2025 | finance.yahoo.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 5.49%May 3, 2025 | aaii.comMise à disposition du rapport financier annuel 2024April 30, 2025 | globenewswire.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 7.06%April 29, 2025 | aaii.comRapport Therapeutics to Participate in Upcoming Investor ConferencesApril 22, 2025 | globenewswire.comMeloni and Trump: An Oval Office Meeting With Rapport and BanterApril 18, 2025 | nytimes.comRapport Therapeutics initiated with an Outperform at Citizens JMPApril 9, 2025 | markets.businessinsider.comBuy Rating for Rapport Therapeutics: Promising Precision Therapeutics for CNS DisordersApril 9, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRAPP, INDV, GLPG, and APGE Company DescriptionsApogee Therapeutics NASDAQ:APGE$41.96 +0.78 (+1.89%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$42.02 +0.05 (+0.13%) As of 06/20/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Galapagos NASDAQ:GLPG$27.42 -0.80 (-2.83%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$27.42 0.00 (0.00%) As of 06/20/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Indivior NASDAQ:INDV$14.01 +0.11 (+0.79%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$13.68 -0.33 (-2.36%) As of 06/20/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Rapport Therapeutics NASDAQ:RAPP$10.92 -0.11 (-1.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$10.90 -0.02 (-0.18%) As of 06/20/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
